Nasal cavity and paranasal sinus squamous cell carcinoma
MONDO:0044787A rare, keratinizing or non-keratinizing squamous cell carcinoma arising from the mucosal epithelium of the nasal cavity or the paranasal sinuses. It affects most often the maxillary sinus. Less frequently, it arises from the nasal cavity, ethmoid sinus, sphenoid sinus, and frontal sinus. Symptoms include nasal fullness, epistaxis, rhinorhea, pain, and paresthesia. Patients with nasal squamous cell carcinoma usually present earlier than patients with maxillary sinus carcinoma and have a better prognosis compared to the latter group.
Also known as: nasal cavity and paranasal sinus squamous cell cancer, nasal cavity and paranasal sinus squamous cell carcinoma
2861 clinical trials for this condition and its sub-types, 9 tagged with Nasal cavity and paranasal sinus squamous cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Nasal cavity and paranasal sinus squamous cell carcinoma
-
New combo therapy aims to tackle rare nasal cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can shrink advanced squamous cell cancers of the nasal cavity and sinuses better than chemotherapy alone. About 35 adults with newly diagnosed, untreated stage II to IVb disease …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can an immunotherapy combo shrink sinonasal tumors before surgery?
Disease control Recruiting nowThis trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can help people with sinonasal cancer, a rare cancer of the nasal cavity and sinuses. Participants receive toripalimab along with carboplatin and docetaxel, then undergo sur…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Personalized vaccine takes on head and neck cancer in early trial
Disease control Recruiting nowThis early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with the immunotherapy drug pembrolizumab, for people with head and neck cancer that has returned or spread. The main goals are to check safety, find the best dose, and see i…
Phase 1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC